argenx to acquire Forte Biosciences for $2.2 billion

1. 1argenx (ARGX) has agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion.
2. 2The deal is an all-cash offer of $77 per share, a roughly 40% premium over Friday's closing price, and has been unanimously approved by both companies' boards.
3. 3The acquisition gives argenx clinical-stage candidates in development for vitiligo and celiac disease, aiming to reduce its reliance on lead drug Vyvgart and expand its immunology pipeline; the transaction is expected to close in the third quarter of 2026.

Source The Wall Street Journal +5 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →